scholarly journals Stasimon Contributes to the Loss of Sensory Synapses and Motor Neuron Death in a Mouse Model of Spinal Muscular Atrophy

2019 ◽  
Author(s):  
Christian Simon ◽  
Meaghan Van Alstyne ◽  
Francesco Lotti ◽  
Elena Bianchetti ◽  
Sarah Tisdale ◽  
...  
Cell Reports ◽  
2019 ◽  
Vol 29 (12) ◽  
pp. 3885-3901.e5 ◽  
Author(s):  
Christian M. Simon ◽  
Meaghan Van Alstyne ◽  
Francesco Lotti ◽  
Elena Bianchetti ◽  
Sarah Tisdale ◽  
...  

2002 ◽  
Vol 25 (5) ◽  
pp. 700-708 ◽  
Author(s):  
S�verine Guettier-Sigrist ◽  
B�n�dicte Hugel ◽  
Gilliane Coupin ◽  
Jean-Marie Freyssinet ◽  
Philippe Poindron ◽  
...  

2018 ◽  
Vol 32 (15-16) ◽  
pp. 1045-1059 ◽  
Author(s):  
Meaghan Van Alstyne ◽  
Christian M. Simon ◽  
S. Pablo Sardi ◽  
Lamya S. Shihabuddin ◽  
George Z. Mentis ◽  
...  

2019 ◽  
Author(s):  
Christian M. Simon ◽  
Meaghan Van Alstyne ◽  
Francesco Lotti ◽  
Elena Bianchetti ◽  
Sarah Tisdale ◽  
...  

AbstractReduced expression of the SMN protein causes spinal muscular atrophy (SMA) – an inherited neurodegenerative disease characterized by multiple synaptic deficits and motor neuron loss. Here, we show that AAV9-mediated delivery of Stasimon – a gene encoding an ER-resident transmembrane protein regulated by SMN – improves motor function in a mouse model of SMA through multiple mechanisms. In proprioceptive neurons of SMA mice, Stasimon overexpression prevents the loss of afferent synapses on motor neurons and enhances sensory-motor neurotransmission. In SMA motor neurons, Stasimon suppresses the neurodegenerative process by selectively reducing phosphorylation but not upregulation of the tumor suppressor p53, both of which are converging events required to trigger neuronal death. We further show that Stasimon deficiency synergizes with SMA-related mechanisms of p53 upregulation to induce phosphorylation of p53. These findings identify Stasimon dysfunction induced by SMN deficiency as an upstream driver of cellular pathways that lead to synaptic loss and motor neuron degeneration, revealing a dual contribution of Stasimon to motor circuit pathology in SMA.


2019 ◽  
Vol 14 (3) ◽  
pp. FNL25
Author(s):  
Joseph M Hoolachan ◽  
Emma R Sutton ◽  
Melissa Bowerman

Spinal muscular atrophy (SMA) is a childhood disorder caused by loss of the SMN gene. Pathological hallmarks are spinal cord motor neuron death, neuromuscular junction dysfunction and muscle atrophy. The first SMN genetic therapy was recently approved and other SMN-dependent treatments are not far behind. However, not all SMA patients will reap their maximal benefit due to limited accessibility, high costs and differential effects depending on timing of administration and disease severity. The repurposing of commercially available drugs is an interesting strategy to ensure more rapid and less expensive access to new treatments. In this mini-review, we will discuss the potential and relevance of repositioning drugs currently used for neurodegenerative, neuromuscular and muscle disorders for SMA.


2009 ◽  
Vol 19 (3) ◽  
pp. 420-433 ◽  
Author(s):  
Lyndsay M. Murray ◽  
Sheena Lee ◽  
Dirk Bäumer ◽  
Simon H. Parson ◽  
Kevin Talbot ◽  
...  

2017 ◽  
Vol 37 (36) ◽  
pp. 8830-8844 ◽  
Author(s):  
Kaori Sugiyama ◽  
Tomomi Aida ◽  
Masatoshi Nomura ◽  
Ryoichi Takayanagi ◽  
Hanns U. Zeilhofer ◽  
...  

Neuroreport ◽  
2009 ◽  
Vol 20 (14) ◽  
pp. 1284-1289 ◽  
Author(s):  
Grace Lee ◽  
Tony Chu ◽  
Christopher A. Shaw

Sign in / Sign up

Export Citation Format

Share Document